PROVECTUS BIOPHARMACEUTICALS, INC.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
PVCT$0.07+3.6%Stored close · as of Jun 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| For the Three Months Ended · For the Nine Months Ended | |||||
|---|---|---|---|---|---|
| September 30, · September 30, | |||||
| 2025 · 2024 · 2025 · 2024 | |||||
| Grant Revenue | $ | - | $109,745 | $336,108 | $602,808 |
| Operating Expenses: | |||||
| Research and development | 345,861 | 413,987 | 1,628,848 | 1,442,449 | |
| General and administrative | 929,746 | 651,486 | 2,881,536 | 1,358,206 | |
| Total Operating Expenses | 1,275,607 | 1,065,473 | 4,510,384 | 2,800,655 | |
| Total Operating Loss | (1,275,607) | (955,728) | (4,174,276) | (2,197,847) | |
| Other Income (Expense): | |||||
| Research and development credit | - | 56 | - | 9,357 | |
| Interest expense | (48,022) | (58,679) | (163,036) | (176,751) | |
| Total Other Income (Expense), Net | (48,022) | (58,623) | (163,036) | (167,394) | |
| Net Loss | (1,323,629) | (1,014,351) | (4,337,312) | (2,365,241) | |
| Net Loss attributable to noncontrolling interest | (12,348) | - | (71,503) | - | |
| Net Loss attributable to common stockholders | $(1,311,281) | $(1,014,351) | $(4,265,809) | $(2,365,241) | |
| Basic and Diluted Loss Per Common Share | $(0.00) | $(0.00) | $(0.01) | $(0.01) | |
| Weighted Average Number of Common | |||||
| Shares Outstanding - Basic and Diluted | 420,279,879 | 419,906,732 | 420,279,879 | 419,651,259 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.